- Home
- DGNX vs MESO Comparison
DGNX vs MESO Comparison
Compare DGNX & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGNX
- MESO
- Stock Information
- Founded
- DGNX 2018
- MESO 2004
- Country
- DGNX United Kingdom
- MESO Australia
- Employees
- DGNX N/A
- MESO N/A
- Industry
- DGNX
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DGNX
- MESO Health Care
- Exchange
- DGNX NYSE
- MESO Nasdaq
- Market Cap
- DGNX 1.2B
- MESO 1.4B
- IPO Year
- DGNX 2025
- MESO N/A
- Fundamental
- Price
- DGNX $45.00
- MESO $10.44
- Analyst Decision
- DGNX
- MESO Buy
- Analyst Count
- DGNX 0
- MESO 4
- Target Price
- DGNX N/A
- MESO $18.00
- AVG Volume (30 Days)
- DGNX 54.9K
- MESO 191.2K
- Earning Date
- DGNX 01-01-0001
- MESO 02-26-2025
- Dividend Yield
- DGNX N/A
- MESO N/A
- EPS Growth
- DGNX N/A
- MESO N/A
- EPS
- DGNX N/A
- MESO N/A
- Revenue
- DGNX $1,177,066.00
- MESO $5,670,000.00
- Revenue This Year
- DGNX N/A
- MESO $178.09
- Revenue Next Year
- DGNX N/A
- MESO $305.06
- P/E Ratio
- DGNX N/A
- MESO N/A
- Revenue Growth
- DGNX N/A
- MESO N/A
- 52 Week Low
- DGNX $3.60
- MESO $5.78
- 52 Week High
- DGNX $155.00
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- DGNX N/A
- MESO 40.14
- Support Level
- DGNX N/A
- MESO $11.70
- Resistance Level
- DGNX N/A
- MESO $12.37
- Average True Range (ATR)
- DGNX 0.00
- MESO 0.44
- MACD
- DGNX 0.00
- MESO -0.04
- Stochastic Oscillator
- DGNX 0.00
- MESO 6.88
About DGNX DIGINEX LIMITED
Diginex Ltd is an investment holding company. It engaged in providing Environmental, Social, and Governance (ESG) reporting solution services, advisory services, and developing customization solutions.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.